Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. Duet BioTherapeutics, a majority-owned subsidiary of Scopus, was launched in September 2021 by Scopus BioPharma to consolidate its immunotherapy assets. These assets include three distinctive complementary CpG-STAT3 inhibitors: RNA silencing – CpG-STAT3siRNA – (“DUET-01”); Antisense – CpG-STAT3ASO – (“DUET-02”); and DNA-binding inhibitor – CpG-STAT3decoy – (“DUET-03”). The Company is also seeking to develop additional drug candidates and to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions.
Company profile
Ticker
SCPS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Scopus Biopharma Inc.
SEC CIK
Corporate docs
Subsidiaries
Vital Spark, Inc. • Scopus BioPharma Israel Ltd. • Duet BioTherapeutics Inc. • Bioscience Oncology Pty Ltd ...
IRS number
821248020
SCPS stock data
Latest filings (excl ownership)
1-Z
Offering exit report
9 Feb 24
15-12G
Securities registration termination
19 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
DEF 14A
Definitive proxy
21 Jul 23
PRER14A
Preliminary revised proxy
28 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
14 Apr 23
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13D
HCFP/Capital Partners 18B-1 LLC
26 Nov 21
4
Ira Scott Greenspan
26 Nov 21
4
Joshua R Lamstein
26 Nov 21
SC 13D/A
SCPS/Strategic Capital Partners LLC
26 Nov 21
SC 13D/A
HCFP/Capital Partners 18B-2 LLC
26 Nov 21
4
Paul Hopper
17 Nov 21
3
Paul Hopper
17 Nov 21
4
Ira Scott Greenspan
30 Aug 21
4
Joshua R Lamstein
27 Aug 21
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 362.10 k | 362.10 k | 362.10 k | 362.10 k | 362.10 k | 362.10 k |
Cash burn (monthly) | 346.46 k | 66.20 k | 976.29 k | 778.58 k | 336.41 k | 253.55 k |
Cash used (since last report) | 3.42 mm | 653.77 k | 9.64 mm | 7.69 mm | 3.32 mm | 2.50 mm |
Cash remaining | -3.06 mm | -291.67 k | -9.28 mm | -7.33 mm | -2.96 mm | -2.14 mm |
Runway (months of cash) | -8.8 | -4.4 | -9.5 | -9.4 | -8.8 | -8.4 |
Institutional ownership, Q3 2022
6.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 1 |
Closed positions | 6 |
Increased positions | 1 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 6.75 mm |
Total shares | 2.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HCFP/Capital Partners 18B-1 | 1.35 mm | $3.71 mm |
SCPS/Strategic Capital Partners | 1.07 mm | $2.94 mm |
Geode Capital Management | 217.08 k | $52.00 k |
M&R Capital Management | 76.82 k | $18.00 k |
Renaissance Technologies | 61.10 k | $15.00 k |
Tower Research Capital | 26.53 k | $6.00 k |
HRT Financial | 14.35 k | $3.00 k |
First Manhattan | 13.10 k | $3.00 k |
NTRS Northern Trust | 12.52 k | $3.00 k |
JPM JPMorgan Chase & Co. | 5.00 k | $1.00 k |